Cue Biopharma Announces Upcoming Participation at Healthcare Forum
Cue Biopharma to Participate in Key Healthcare Conference
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a dynamic biotech firm in the clinical stage, is set to engage in a vital fireside chat at the Cantor Global Healthcare Conference. This event is scheduled to take place in New York, from September 3rd to 5th, 2025. The opportunity comes as Cue Biopharma continues its commitment to developing innovative therapeutic biologics aimed at modulating disease-specific T cells for the treatment of autoimmune diseases and cancer.
Significant Updates and Presentations
During this session, company representatives will share important updates regarding their leading program within the Immuno-STAT platform. A key highlight of the fireside chat will be the advancements surrounding CUE-401, which is recognized as the company’s primary asset focused on autoimmune challenges.
Event Details
Cantor Global Healthcare Conference
Date: Friday, September 5, 2025
Time: 8:00 a.m. – 8:30 a.m. EDT
Presenter: Daniel Passeri, Chief Executive Officer
Link to Webcast: https://stream.onstreammedia.com/onsm/GetReport?customerId=22&eventId=15390931
Access to Webcast
A live and archived version of this fireside chat will be made accessible on the Company’s official website, located within the News and Events section, ensuring both real-time and post-event access for those interested. The archived content will remain available for a period of 30 days following the event.
About Cue Biopharma
Cue Biopharma prides itself on being at the forefront of biopharmaceutical innovation. With a distinctive approach, they are dedicated to developing injectable biologics that specifically engage and modulate disease-related T cells directly in patients. The Immuno-STAT platform—standing for Selective Targeting and Alteration of T cells—shows great promise as it aims to utilize the body's immune system without triggering widespread systemic effects.
Company Background and Expertise
Based in Boston, Cue Biopharma benefits from the guidance of a highly skilled management team. Their expertise spans immunology, protein engineering, and design, along with clinical development of protein biologics, positioning the company for future success in the biomedical field.
Contact Information
Investor Contact:
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact:
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
Frequently Asked Questions
What is the focus of Cue Biopharma?
Cue Biopharma specializes in developing biologics that target disease-specific T cells for treating autoimmune conditions and cancer.
When will Cue Biopharma present at the Cantor Global Healthcare Conference?
The presentation will take place on Friday, September 5, 2025, from 8:00 a.m. to 8:30 a.m. EDT.
Where can I watch the fireside chat?
The chat will be available live and archived on the Company’s website for 30 days post-event.
What is the Immuno-STAT platform?
Immuno-STAT is Cue Biopharma’s proprietary platform aimed at engaging and modulating T cell responses in a precise manner, minimizing side effects from broad immune suppression.
Who is the CEO of Cue Biopharma?
Daniel Passeri serves as the Chief Executive Officer of Cue Biopharma, leading efforts in innovation and strategic direction.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.